Welcome to the e-CCO Library!

P500: Capsule endoscopy reveals small intestinal mucosal Crohn’s disease healing after treatment with adalimumab: preliminary results of the SIMCHA study
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

E. Seidman*1, U. Kopylov2, C.-Y. Chao1, M. Girardin3, M. Starr4

Created: Friday, 22 February 2019, 9:49 AM
P500: Effectiveness and safety in Crohn's disease patients who were treated with CT-P13
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Choe Y.H.*1, Lee S.-H.2, Park D.I.3, Lee J.H.4, Kim H.J.5, Kim Y.-H.6, Choi C.H.7, Eun C.S.8, Lee S.J.9, Lee S.9

Created: Wednesday, 20 February 2019, 10:36 AM
P500: Post-marketing safety experience of vedolizumab in patients receiving concomitant treatment with other biologics
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. D. Cohen1, F. Bhayat2, A. Blake2, S. Travis*3

Created: Friday, 22 February 2019, 9:41 AM
P500: Real life 2 year experience with ustekinumab in a Spanish open-label cohort of ulcerative colitis patients.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Iborra Colomino, M.I.(1)*;Ferreiro-Iglesias, R.(2);Martín-Arranz, M.D.(3);Mesonero-Gismero, F.(4);Mínguez, A.(1);Porto Silva, S.(2);García-Ramírez, L.(5);García de la Filia, I.(4);Bastida, G.(1);Nieto García, L.(2);Suárez Ferrer, C.(3);Aguas, M.(1);Barreiro de Acosta, M.(2);Nos, P.(1);
Created: Friday, 14 July 2023, 11:05 AM
P500: The effects of EBV naïve status on treatment decisions in patients with inflammatory bowel disease: Does the risk of GI lymphoma justify the cost?
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Ahmed1, F. Brown1, R. Ahmed1, S. Whitehead2, H. Steed1, M.J. Brookes1*

Created: Thursday, 21 February 2019, 9:14 AM
P500: The use of budesonide results in lower risk for infections compared to systemic glucocorticoids
Year: 2022
Source: ECCO'22
Authors: Pallmer, K.(1);Timeus, S.(2);Laoun, R.(1);
Created: Friday, 11 February 2022, 3:56 PM
P501 Thiopurine withdrawal in patients with Crohn’s disease: the SURESTE study
Year: 2020
Source:

ECCO'20 Vienna

Authors:

E. Sánchez Rodríguez1, R. Sánchez Aldehuelo1, J. Guardiola2, A. Gutiérrez Casbas3, E. Domènech4, F. Bermejo5, M. Van-Domselaar6, F. Mesonero Gismero1, G. Suris2, R. Muñoz Perez3, M. Mañosa4, L. Jiménez Márquez5, A. Algaba García5, A. López sanroman1, SURESTE

Created: Thursday, 30 January 2020, 10:12 AM
P501: Abdominal obesity in Paediatric Crohn’s disease is associated with adipokine dysregulation
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

D. Thangarajah*1, K. E. Chapell1, S. Mandalia1, G. Frost2, J. M. Fell3

Created: Friday, 22 February 2019, 9:49 AM
P501: Baseline characteristics of Crohn's disease patients in the vedolizumab PASS study: a cohort study assessing the safety and effectiveness of vedolizumab compared to other biologic agents (02)
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Siegel C.A.*1, Lichtenstein G.2, Siegmund B.3, Lewis J.D.2, Wolf D.4, Louis E.5, Sebastian S.6, Hebuterne X.7, Bell A.8, Söderman C.9, Schubert S.10, Atreya R.11, Polyak S.12, Hoque S.13, Krummenerl A.14, Bokemeyer B.15, Krummenerl T.16, Shulmann S.17, Karlén P.18, Moum B.19, Dolin P.20

Created: Wednesday, 20 February 2019, 10:36 AM
P501: High TNF-production of CD14+ cells and short disease duration are independent predictive factors for response to Infliximab treatment
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

D. Lissner*1, B. Jessen1,2, E. Sonnenberg1, M. Schumann1, F. Schmidt1, Y. Rodriguez Sillke1, B. Siegmund1

Created: Friday, 22 February 2019, 9:41 AM
P501: Incidence and therapeutic management/treatment of very early onset inflammatory bowel disease during 2015-2020.
Year: 2021
Source: ECCO'21 Virtual
Authors: Ninh, G.(1);Wewer, V.(1);Jakobsen, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P501: Safety of peri-operative biologics in patients with IBD undergoing resective bowel surgery: experiences of a single center cohort
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Ochsenkuehn, T.(1)*;Tillack-Schreiber, C.(2);Bader, F.(3);Maximilian, S.(3);Szokodi, D.(4);Tomelden, J.(5);Waggershauser, C.(6);Braun, I.(4);Schnitzler, F.(7);
Created: Friday, 14 July 2023, 11:05 AM
P501: Vedolizumab for UC after infliximab failure in PSC patients after OLTx: Two case reports
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Drastich*, J. Brezina, L. Bajer, M. Benes, J. Spicak

Created: Thursday, 21 February 2019, 9:14 AM
P501: Vedolizumab is associated with longer drug sustainability compared to infliximab in moderate-to-severe Ulcerative Colitis: a real-world cohort study
Year: 2022
Source: ECCO'22
Authors: Konikoff, T.(1);Yanai, H.(1);Banai, H.(1);Avni-Biron, I.(1);Snir, Y.(1);Broitman, L.(1);Barkan, R.(1);Checholin, L.(1);Dotan, I.(1);Ollech, J.(2);
Created: Friday, 11 February 2022, 3:56 PM
P502 Tumour necrosis factor antagonists are superior to anti-integrin and anti-IL-12/23 therapies for preventing postoperative recurrence in adult Crohn’s disease patients requiring postoperative therapy
Year: 2020
Source:

ECCO'20 Vienna

Authors:

T. Nakamura1, R. Shah2, M. Sachs3, S. Chang4, D. Hudesman4, B. Click5, J. Axelrad4

Created: Thursday, 30 January 2020, 10:12 AM
P502: Application of an algorithm-based precision-dosing model to a real-world cohort of patients on infliximab maintenance therapy: implications for drug usage and cost
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Nguyen, A.(1,2,3)*;Gibson, P.(1,2);Upton , R.(4,5);Mould, D.(4);Sparrow, M.P.(1,2);
Created: Friday, 14 July 2023, 11:05 AM
P502: Clinical and endoscopic features of secondary loss of response cases in patients with Crohn’s disease treated with infliximab by top-down strategy: A case–control study
Year: 2018
Source: ECCO '18 Vienna
Authors:

T. Miyazaki1*, A. Fujimori1, R. Koshiba1, K. Fujimoto1, T. Sato1, M. Kawai2, Y. Kita1, K. Kamikozuru1, T. Takagawa2, Y. Yokoyama1, N. Hida1, K. Watanabe2, S. Nakamura1

Created: Thursday, 21 February 2019, 9:14 AM
P502: Correlation between soluble suppression of tumorigenicity 2 (sST2) and endoscopic activity in patients with moderate to severe ulcerative colitis under golimumab treatment: results of the EVOLUTION study
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

F. Magro*1,2, S. Lopes1, M. Silva1, R. Coelho1, F. Portela3, D. Branquinho3, L. Correia4, S. Fernandes4, M. Cravo5, P. Caldeira6, H. Sousa6,7, M. Patita8, P. Lago9, J. Ramos10, J. Afonso2, I. Redondo11, P. Machado11, G. Philip12, J. Lopes2, F. Carneiro2,13

Created: Friday, 22 February 2019, 9:41 AM
P502: Dietary habits and nutritional status in children and adolescents with Inflammatory Bowel Disease: an italian multicenter case-control study (NUTRIBD study)
Year: 2021
Source: ECCO'21 Virtual
Authors: Gatti, S.(1);Vallorani, M.(1);zoppi, E.(1);aloi, M.(2);bramuzzo, M.(3);felici, E.(4);panceri, R.(5);ciacchini, B.(6);catassi, G.(2);grazian, F.(3);catassi, C.(1);
Created: Wednesday, 2 June 2021, 4:12 PM
P502: Different presentation of tuberculosis associated with anti-TNF therapy among patients with Inflammatory Bowel Disease in endemic area: observation from China
Year: 2022
Source: ECCO'22
Authors: Ye, L.(1,2);Wu, L.(3);Tang, J.(4);Mao, R.(5);Cao, Q.(3);
Created: Friday, 11 February 2022, 3:56 PM